BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 23341375)

  • 1. Value of fluorescence cystoscopy in high risk non-muscle invasive bladder cancer.
    Mayr R; Burger M
    Curr Urol Rep; 2013 Apr; 14(2):90-3. PubMed ID: 23341375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral 5-aminolevulinic acid in simultaneous photodynamic diagnosis of upper and lower urinary tract transitional cell carcinoma - a prospective audit.
    Ahmad S; Aboumarzouk O; Somani B; Nabi G; Kata SG
    BJU Int; 2012 Dec; 110(11 Pt B):E596-600. PubMed ID: 22758907
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hexyl aminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: a critical review of the current literature.
    Rink M; Babjuk M; Catto JW; Jichlinski P; Shariat SF; Stenzl A; Stepp H; Zaak D; Witjes JA
    Eur Urol; 2013 Oct; 64(4):624-38. PubMed ID: 23906669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Innovations in the endoscopic management of bladder cancer: is the era of white light cystoscopy over.
    Soria F; Gurioli A; Peraldo F; Oderda M; Giona S; Ambrosini E; Frea B; Gontero P
    Urologia; 2013 Jun; 80 Spec No 1():1-8. PubMed ID: 23813287
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective randomized trial of hexylaminolevulinate photodynamic-assisted transurethral resection of bladder tumour (TURBT) plus single-shot intravesical mitomycin C vs conventional white-light TURBT plus mitomycin C in newly presenting non-muscle-invasive bladder cancer.
    O'Brien T; Ray E; Chatterton K; Khan MS; Chandra A; Thomas K
    BJU Int; 2013 Dec; 112(8):1096-104. PubMed ID: 24053153
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New optical imaging technologies for bladder cancer: considerations and perspectives.
    Liu JJ; Droller MJ; Liao JC
    J Urol; 2012 Aug; 188(2):361-8. PubMed ID: 22698620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimised photodynamic diagnosis for transurethral resection of the bladder (TURB) in German clinical practice: results of the noninterventional study OPTIC III.
    Bach T; Bastian PJ; Blana A; Kaminsky A; Keller S; Knoll T; Lang C; Promnitz S; Ubrig B; Keller T; Qvick B; Burger M;
    World J Urol; 2017 May; 35(5):737-744. PubMed ID: 27578233
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Real-life experience': recurrence rate at 3 years with Hexvix
    Gallagher KM; Gray K; Anderson CH; Lee H; Stewart S; Donat R; Mariappan P
    World J Urol; 2017 Dec; 35(12):1871-1877. PubMed ID: 28803385
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photodynamic diagnosis in non-muscle-invasive bladder cancer: a systematic review and cumulative analysis of prospective studies.
    Kausch I; Sommerauer M; Montorsi F; Stenzl A; Jacqmin D; Jichlinski P; Jocham D; Ziegler A; Vonthein R
    Eur Urol; 2010 Apr; 57(4):595-606. PubMed ID: 20004052
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Cost-effectiveness of transurethral resection of the bladder with blue light in patients with non muscle invasive bladder cancer in France].
    Rouprêt M; Malavaud B; Molinier L; Leleu H; Blachier M; Marteau F
    Prog Urol; 2015 Apr; 25(5):256-64. PubMed ID: 25605343
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hexaminolevulinate blue light cystoscopy (Hal) assisted transurethral resection of the bladder tumour vs white light transurethral resection of the bladder tumour in non-muscle invasive bladder cancer (NMIBC) : a retrospective analysis.
    Capece M; Spirito L; La Rocca R; Napolitano L; Buonopane R; Di Meo S; Sodo M; Bracale U; Longo N; Palmieri A; Fusco F; Verze P; Califano G; Crocetto F; Imbimbo C; Mirone V; Imperatore V; Creta M
    Arch Ital Urol Androl; 2020 Apr; 92(1):17-20. PubMed ID: 32255316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Budget impact of incorporating one instillation of hexaminolevulinate hydrochloride blue-light cytoscopy in transurethral bladder tumour resection for patients with non-muscle-invasive bladder cancer in Sweden.
    Rose JB; Armstrong S; Hermann GG; Kjellberg J; Malmström PU
    BJU Int; 2016 Jun; 117(6B):E102-13. PubMed ID: 26305667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Fluorescence cystoscopy at bladder cancer: present trials].
    Zaak D; Karl A; Stepp H; Tritschler S; Tilki D; Burger M; Knuechel R; Stief C
    Urologe A; 2007 Nov; 46(11):1519-27. PubMed ID: 17928985
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-aminolaevulinic acid-induced fluorescence cystoscopy during transurethral resection reduces the risk of recurrence in stage Ta/T1 bladder cancer.
    Babjuk M; Soukup V; Petrík R; Jirsa M; Dvorácek J
    BJU Int; 2005 Oct; 96(6):798-802. PubMed ID: 16153204
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Fluorescence diagnosis in patients with non-muscle invasive bladder cancer: results of a metaanalysis].
    Kausch I; Sommerauer M; Montorsi F; Stenzl A; Jacqmin D; Jichlinski P; Jocham D; Ziegler A; Vonthein R
    Aktuelle Urol; 2010 May; 41(3):171-7. PubMed ID: 20486035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seven years' experience with 5-aminolevulinic acid in detection of transitional cell carcinoma of the bladder.
    Hungerhuber E; Stepp H; Kriegmair M; Stief C; Hofstetter A; Hartmann A; Knuechel R; Karl A; Tritschler S; Zaak D
    Urology; 2007 Feb; 69(2):260-4. PubMed ID: 17320660
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Value of the photodynamic method in the diagnosis of superficial bladder tumors].
    Lipiński MI; Jeromin LM
    Wiad Lek; 2004; 57 Suppl 1():192-5. PubMed ID: 15884237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hexylaminolaevulinate 'blue light' fluorescence cystoscopy in the investigation of clinically unconfirmed positive urine cytology.
    Ray ER; Chatterton K; Khan MS; Thomas K; Chandra A; O'Brien TS
    BJU Int; 2009 May; 103(10):1363-7. PubMed ID: 19076151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.